Results

1–10 of 53 results for safety

Pegcetacoplan Safety: Panel Recap
Andre J. Witkin, MD
Updates from the Field
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Dropless Vitrectomy Surgery for Epiretinal Membranes: Efficacy and Safety Compared to Standard of Care
K. V. Chalam, MD, PhD, MBA, FRCS(C), FASRS
Annual Meeting Talks
2022
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD
Annual Meeting Talks
2022
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
Exclusive Use of 27-Gauge Instruments for All Vitrectomy Indications: Safety and Efficacy Assessment
On Demand Cases, Courses, and Papers
2022